More efficacious and better tolerated treatments for epilepsy are clearly needed. Complementary and alternative medicine (CAM) has a long history of use in certain parts of the world and has gained increasing interest over the last decades in Western countries. In countries with a Western-based type of medical system, people with epilepsy (PWE) take natural products or engage in other forms of CAM mainly to enhance general health, but also to prevent seizures or to alleviate symptoms of comorbidities or side effects of antiepileptic medications. In other countries, well developed medical systems, such as traditional Chinese Medicine and Ayurveda, are often the basis for treating PWE. Based on anecdotal reports of efficacy in PWE, natural products from these and other traditions are increasingly being studied in animal models of epilepsy, and candidates for further clinical development have been identified. It is likely, therefore, that natural products will be further evaluated for safety, tolerability and efficacy in PWE with drug-resistant seizures.
References
[1]
Kwan, P.; Brodie, M.J. Early identification of refractory epilepsy. N. Engl. J. Med.？2000, 342, 314–319.
[2]
Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen Hauser, W.; Mathern, G.; Moshe, S.L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies. Epilepsia？2009. [Epub ahead of print].
[3]
Engel, J., Jr.; Wiebe, S.; French, J.; Sperling, M.; Williamson, P.; Spencer, D.; Gumnit, R.; Zahn, C.; Westbrook, E.; Enos, B. Quality Standards Subcommittee of the American Academy of Neurology, American Epilepsy Society, American Association of Neurological Surgeons: Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology？2003, 60, 538–547. 12601090
[4]
Choi, H.; Sell, R.L.; Lenert, L.; Muennig, P.; Goodman, R.R.; Gilliam, F.G.; Wong, J.B. Epilepsy surgery for pharmacoresistant temporal lobe epilepsy: A decision analysis. JAMA？2008, 300, 2497–2505.
[5]
Engel, J., Jr. Surgical treatment for epilepsy: too little, too late? JAMA？2008, 300, 2548–2550, doi:10.1001/jama.2008.756. 19050199
[6]
Boon, P.; Raedt, R.; de Herdt, V.; Wyckhuys, T.; Vonck, K. Electrical stimulation for the treatment of epilepsy. Neurotherapeutics？2009, 6, 218–227.
[7]
Schmidt, D. Drug treatment of epilepsy: Options and limitations. Epilepsy Behav.？2009, 15, 56–65.
[8]
National Institutes of Health in National Center for Complementary and Alternatice Medicine Home Page. Available online: http://nccam.nih.gov/.
[9]
Devinsky, O.; Schachter, S.C.; Pacia, S. Complementary and Alternative Therapies for Epilepsy.; Demos Medical Pub.: New York, NY, USA, 2005.
[10]
Cheuk, D.K.; Wong, V. Acupuncture for epilepsy. Cochrane Database Syst. Rev.？2008.
[11]
Ramaratnam, S.; Sridharan, K. Yoga for epilepsy. Cochrane Database Syst. Rev.？2000.
[12]
Li, Q.; Chen, X.; He, L.; Zhou, D. Traditional Chinese medicine for epilepsy. Cochrane Database Syst. Rev.？2009.
[13]
Barnes, P.M.; Bloom, B.; Nahin, R.L. Complementary and alternative medicine use among adults and children: United States, 2007. Natl. Health Stat. Report？, 10(12), 1–23.
[14]
Nahin, R.L.; Barnes, P.M.; Stussman, B.J.; Bloom, B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl. Health Stat. Report？2009, (18), 1–14.
[15]
Melchart, D.; Linde, K.; Fischer, P.; Kaesmayr, J. Echinacea for preventing and treating the common cold. Cochrane Database Syst. Rev.？2000, (2), CD000530. 10796553
[16]
Linde, K.; Barrett, B.; Wolkart, K.; Bauer, R.; Melchart, D. Echinacea for preventing and treating the common cold. Cochrane Database Syst. Rev.？2006, (1), CD000530. 16437427
[17]
Patel, J.V.; Tracey, I.; Hughes, E.A.; Lip, G.Y. Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. Vasc. Health Risk Manag.？2009, 5, 801–810.
[18]
Marchioli, R.; Barzi, F.; Bomba, E.; Chieffo, C.; Di Gregorio, D.; Di Mascio, R.; Franzosi, M.G.; Geraci, E.; Levantesi, G.; Maggioni, A.P.; Mantini, L.; Marfisi, R.M.; Mastrogiuseppe, G.; Mininni, N.; Nicolosi, G.L.; Santini, M.; Schweiger, C.; Tavazzi, L.; Tognoni, G.; Tucci, C.; Valagussa, F. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation？2002, 105, 1897–1903.
[19]
Macchia, A.; Levantesi, G.; Franzosi, M.G.; Geraci, E.; Maggioni, A.P.; Marfisi, R.; Nicolosi, G.L.; Schweiger, C.; Tavazzi, L.; Tognoni, G.; Valagussa, F.; Marchioli, R. GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur. J. Heart Fail.？2005, 7, 904–909, doi:10.1016/j.ejheart.2005.04.008. 16087142
[20]
Studer, M.; Briel, M.; Leimenstoll, B.; Glass, T.R.; Bucher, H.C. Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch. Intern. Med.？2005, 165, 725–730.
[21]
Gidal, B.E.; Sheth, R.D.; Bainbridge, J.; Ramsay, E.; Welty, T.E.; Weatherford, K.J.; Gilliam, F.; Gallo, B.V.; Alldredge, B.K.; Montouris, G.D.; Belden, D.S.; Lenners, A. Alternative Medicine (AM) Use in Epilepsy: Results of a National, Multicenter Survey. Epilepsia？1999, 40, 107–108.
[22]
Peebles, C.T.; McAuley, J.W.; Roach, J.; Moore, J.L.; Reeves, A.L. Alternative Medicine Use by Patients with Epilepsy. Epilepsy Behav.？2000, 1, 74–77.
[23]
Sirven, J.I.; Drazkowski, J.F.; Zimmerman, R.S.; Bortz, J.J.; Shulman, D.L.; Macleish, M. Complementary/alternative medicine for epilepsy in Arizona. Neurology？2003, 61, 576–577.
[24]
Plunkett, M.V.; Klein, E.W.; Alldredge, B.K. Use of Complementary and Alternative Medicine Products by Persons with Epilepsy. Epilepsia？2004, 45, 148–149.
[25]
Easterford, K.; Clough, P.; Comish, S.; Lawton, L.; Duncan, S. The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy. Epilepsy Behav.？2005, 6, 59–62.
[26]
Liow, K.; Ablah, E.; Nguyen, J.C.; Sadler, T.; Wolfe, D.; Tran, K.D.; Guo, L.; Hoang, T. Pattern and frequency of use of complementary and alternative medicine among patients with epilepsy in the midwestern United States. Epilepsy Behav.？2007, 10, 576–582.
[27]
Murphy, S.M.; Rogers, A.; Hutchinson, M.; Tubridy, N. Counting the cost of complementary and alternative therapies in an Irish neurological clinic. Eur. J. Neurol.？2008, 15, 1380–1383.
[28]
Kaiboriboon, K.; Guevara, M.; Alldredge, B.K. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia？2009, 50, 1927–1932.
[29]
Waaler, P.E.; Blom, B.H.; Skeidsvoll, H.; Mykletun, A. Prevalence, classification, and severity of epilepsy in children in western Norway. Epilepsia？2000, 41, 802–810, doi:10.1111/j.1528-1157.2000.tb00246.x. 10897150
[30]
Gross-Tsur, V.; Lahad, A.; Shalev, R.S. Use of complementary medicine in children with attention deficit hyperactivity disorder and epilepsy. Pediatr. Neurol.？2003, 29, 53–55.
[31]
Yuncker, L.A.; Kerszberg, S.; Hunt, S.L.; Lehman, E.B.; Barron, T.F. The Use of Alternative/Complementary Therapies in Children with Epilepsy and other Neurologic Disorders. Epilepsia？2004, 45, 326–327.
[32]
Rhodes, P.J.; Small, N.; Ismail, H.; Wright, J.P. The use of biomedicine, complementary and alternative medicine, and ethnomedicine for the treatment of epilepsy among people of South Asian origin in the UK. BMC Complement Altern. Med.？2008, 8, 7, doi:10.1186/1472-6882-8-7. 18366698
[33]
Prus, N.; Grant, A.C. Patient beliefs about epilepsy and brain surgery in a multicultural urban population. Epilepsy Behav.？2010, 17, 46–49.
[34]
Cohen, M.H. Regulation, religious experience, and epilepsy: A lens on complementary therapies. Epilepsy Behav.？2003, 4, 602–606, doi:10.1016/j.yebeh.2003.08.014. 14698692
[35]
LaFrance, W.C., Jr.; Kanner, A.M.; Hermann, B. Psychiatric comorbidities in epilepsy. Int. Rev. Neurobiol.？2008, 83, 347–383.
[36]
Harms, S.L.; Eberly, L.E.; Garrard, J.M.; Hardie, N.A.; Bland, P.C.; Leppik, I.E. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. J. Am. Geriatr. Soc.？2005, 53, 1023–1028.
[37]
Ivetic, V.; Popovic, M.; Mimica-Dukic, N.; Barak, O.; Pilija, V., St. John's wort (Hypericum perforatum L.) and kindling epilepsy in rabbit. Phytomedicine？2002, 9, 496–499, doi:10.1078/09447110260572985. 12403157
[38]
Borrelli, F.; Izzo, A.A. Herb-drug interactions with St John's wort (Hypericum perforatum): An update on clinical observations. AAPS J.？2009, 11, 710–727.
[39]
Hinnell, C.; Williams, J.; Metcalfe, A.; Patten, S.B.; Parker, R.; Wiebe, S.; Jette, N. Health status and health-related behaviors in epilepsy compared to other chronic conditions-A national population-based study. Epilepsia？2010, 51(5), 853–861. 20067511
[40]
Peled, N.; Shorer, Z.; Peled, E.; Pillar, G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia？2001, 42, 1208–1210.
[41]
Spinella, M. Herbal Medicines and Epilepsy: The Potential for Benefit and Adverse Effects. Epilepsy Behav.？2001, 2, 524–532.
[42]
Eadie, M.J. Could valerian have been the first anticonvulsant? Epilepsia？2004, 45, 1338–1343, doi:10.1111/j.0013-9580.2004.27904.x. 15509234
[43]
Sheldon, S.H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet？1998, 351, 1254.
[44]
Puri, B.K. The safety of evening primrose oil in epilepsy. Prostaglandins Leukot Essent Fatty Acids？2007, 77, 101–103.
[45]
Zhang, Z.; Lian, X.Y.; Li, S.; Stringer, J.L. Characterization of chemical ingredients and anticonvulsant activity of American skullcap (Scutellaria lateriflora). Phytomedicine？2009, 16, 485–493.
[46]
Kiani, J.; Imam, S.Z. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr. J.？2007, 6, 33.
[47]
Zanoli, P.; Rivasi, M.; Zavatti, M.; Brusiani, F.; Baraldi, M. New insight in the neuropharmacological activity of Humulus lupulus L. J. Ethnopharmacol.？2005, 102, 102–106.
[48]
Taha, A.Y.; Ciobanu, F.A.; Saxena, A.; McIntyre Burnham, W. Assessing the link between omega-3 fatty acids, cardiac arrest, and sudden unexpected death in epilepsy. Epilepsy Behav.？2009, 14, 27–31, doi:10.1016/j.yebeh.2008.10.012. 18992844
[49]
Haller, C.A.; Meier, K.H.; Olson, K.R. Seizures reported in association with use of dietary supplements. Clin. Toxicol. (Phila)？2005, 43, 23–30. 15732443
[50]
Jain, S. Ayurveda: The ancient indian system of medicine. In Complementary and Alternative Therapies for Epilepsy; Devinsky, O., Schachter, S.C., Pacia, S., Eds.; Demos Medical Pub.: New York, NY, USA, 2005; pp. 123–128.
[51]
Schachter, S.C.; Acevedo, C.; Acevedo, K.A.; Lai, C.; Diop, A.G. Complementary and alternative medical therapies. In Epilepsy: A Comprehensive Textbook, 2nd ed.; Engel, J., Pedley, T.A., Eds.; Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2008; pp. 1407–1414.
[52]
Wang, S.; Li, Y. Traditional chinese medicine. In Complementary and Alternative Therapies for Epilepsy; Devinsky, O., Schachter, S.C., Pacia, S., Eds.; Demos Medical Pub.: New York, NY, USA, 2005; pp. 177–182.
[53]
Millogo, A.; Kabore, J.; Traore, E.D.; Druet-Cabanac, M.; Preux, P.M. Sociocultural aspects of epilepsy in secondary school students in Bobo-Dioulasso (Burkina Faso). Rev. Neurol. (Paris)？2002, 158, 1186–1190.
[54]
Baskind, R.; Birbeck, G. Epilepsy care in Zambia: A study of traditional healers. Epilepsia？2005, 46, 1121–1126.
[55]
Moshi, M.J.; Kagashe, G.A.; Mbwambo, Z.H. Plants used to treat epilepsy by Tanzanian traditional healers. J. Ethnopharmacol.？2005, 97, 327–336.
[56]
Stafford, G.I.; Pedersen, M.E.; van Staden, J.; Jager, A.K. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J. Ethnopharmacol.？2008, 119, 513–537.
[57]
Pedersen, M.E.; Vestergaard, H.T.; Hansen, S.L.; Bah, S.; Diallo, D.; Jager, A.K. Pharmacological screening of Malian medicinal plants used against epilepsy and convulsions. J. Ethnopharmacol.？2009, 121, 472–475.
[58]
Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available online: http://www.fda.gov/ohrms/dockets/98fr/cf0441.pdf.
[59]
Garrard, J.; Harms, S.; Eberly, L.E.; Matiak, A. Variations in product choices of frequently purchased herbs: caveat emptor. Arch. Intern. Med.？2003, 163, 2290–2295.
[60]
Guidance for Industry. Botanical drug products. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070491.pdf.
[61]
Striano, P.; Striano, S. New and investigational antiepileptic drugs. Expert Opin. Investig. Drugs？2009, 18, 1875–1884.
[62]
Awad, R.; Ahmed, F.; Bourbonnais-Spear, N.; Mullally, M.; Ta, C.A.; Tang, A.; Merali, Z.; Maquin, P.; Caal, F.; Cal, V.; Poveda, L.; Vindas, P.S.; Trudeau, V.L.; Arnason, J.T. Ethnopharmacology of Q'eqchi' Maya antiepileptic and anxiolytic plants: Effects on the GABAergic system. J. Ethnopharmacol.？2009, 125, 257–264.
[63]
Sucher, N.J. Insights from molecular investigations of traditional Chinese herbal stroke medicines: Implications for neuroprotective epilepsy therapy. Epilepsy. Behav.？2006, 8, 350–362.
[64]
Bialer, M.; Johannessen, S.I.; Levy, R.H.; Perucca, E.; Tomson, T.; White, H.S. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res.？2009, 83, 1–43.
[65]
Park, P.; Schachter, S.; Yaksh, T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci. Lett.？2010, 470, 6–9.
